Holen Sie sich die Stockscreener-App
21.54
7.59%
1.52
Handel nachbörslich:
21.54
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$20.02
Offen:
$20.41
24-Stunden-Volumen:
1.33M
Relative Volume:
0.75
Marktkapitalisierung:
$1.90B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-4.7341
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
+0.61%
1M Leistung:
+48.55%
6M Leistung:
+14.88%
1J Leistung:
+241.90%
1-Tages-Spanne:
$20.40
$21.80
1-Wochen-Bereich:
$19.65
$21.80
52-Wochen-Spanne:
$6.01
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.54 | 1.90B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere, CSL gets standard EU approval for kidney disorder treatment - MSN
Travere Therapeutics to Participate at Upcoming Investor ConferencesMay 7, 2025 - BioSpace
Travere Therapeutics to Participate at Upcoming Investor Conferences | TVTX Stock News - GuruFocus
Homocystinuria Market Growth, Trends & Forecast 2025 | Leading - openPR.com
Travere therapeutics CEO sells $398k in stock By Investing.com - Investing.com Nigeria
Travere therapeutics CEO sells $398k in stock - Investing.com Australia
Travere therapeutics CFO sells shares worth $37,553 - Investing.com Australia
Travere therapeutics CFO sells shares worth $37,553 By Investing.com - Investing.com India
Travere Therapeutics Executives Sell Shares - TradingView
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
(TVTX) Technical Data - news.stocktradersdaily.com
Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report - Yahoo
Travere Therapeutics (TVTX) Sees Promising Growth with FILSPARI - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Travere Therapeutics (TVTX) Rating and Price Target Update by We - GuruFocus
Travere Therapeutics (TVTX) Price Target Raised by Stifel | TVTX Stock News - GuruFocus
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst ... - Yahoo
Travere Therapeutics Inc (TVTX) Q1 2025 Earnings Call Highlights: Robust Sales Growth Amidst Challenges - GuruFocus
Travere: Q1 Earnings Snapshot - Norwalk Hour
Travere Therapeutics Reports Strong Q1 2025 Financial Results - TipRanks
Travere Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Travere Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) - Seeking Alpha
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast By Investing.com - Investing.com South Africa
Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Travere Therapeutics Reports First Quarter 2025 Financial Results - BioSpace
Earnings call transcript: Travere Therapeutics beats Q1 2025 EPS forecast - Investing.com
Travere Therapeutics (TVTX) Surpasses Revenue Expectations in Q1 - GuruFocus
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (TVTX) Travere Therapeutics Q1 Adjusted Loss Per Share $0.19 vs. FactSet Est Loss $0.36 - marketscreener.com
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Gains Standard EU Approval for Filsp - GuruFocus
European Commission Grants Standard Approval for Travere's Filsp - GuruFocus
Travere, CSL get standard EU nod for kidney drug (TVTX:NASDAQ) - Seeking Alpha
Travere, CSL Vifor Receive EU Marketing Approval for Filspari in IgA Nephropathy - marketscreener.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval - GuruFocus
Travere Therapeutics (TVTX) Gains Standard EU Approval for Filspari | TVTX Stock News - GuruFocus
How to interpret Travere Therapeutics Inc (TVTX)’s stock chart patterns - uspostnews.com
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy | TVTX Stock News - GuruFocus
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy - Business Wire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy - The Manila Times
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy | CSLLY Stock News - GuruFocus
Cantor Fitzgerald maintains overweight on Travere Therapeutics stock By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) – Research Analysts’ Recent Ratings Updates - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):